Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Inflammatory Bowel Diseases

Free Subscription 30.03.2026 1 BMC Gastroenterol 1 Br J Surg 1 Clin Gastroenterol Hepatol 4 Dig Dis Sci 4 Eur J Gastroenterol Hepatol 1 Gastroenterology 2 Inflamm Bowel Dis 2 J Clin Gastroenterol 8 J Crohns Colitis 1 J Gastroenterol 1 Scand J Gastroenterol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Gastroenterol

1. HU X, Ding J, Liu X
   Diagnostic value of CT enterography combined with inflammatory indicators in active Crohn's disease.
   BMC Gastroenterol. 2026 Mar 24. doi: 10.1186/s12876-026-04750.
   PubMed        
   
   

   
   Br J Surg

2. NG JCK, Morton AJ, Crooks CJ, West J, et al
   Diagnosis of inflammatory bowel disease following symptomatic faecal immunochemical testing - A population based cohort study.
   Br J Surg. 2026 Mar 26:znag039. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Clin Gastroenterol Hepatol

3. SANDS BE, Schreiber S, Dubinsky MC, D'Haens G, et al
   Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD Study.
   Clin Gastroenterol Hepatol. 2026;24:1111-1120.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

4. ALMUSABEH H, Kovach Z, Lloyd L, Alzaher MZ, et al
   Risk of Autoimmune Hepatitis Among Patients with Inflammatory Bowel Disease Treated with Infliximab: A Retrospective Cohort Study Using a National Database.
   Dig Dis Sci. 2026 Mar 25. doi: 10.1007/s10620-026-09854.
   PubMed         Abstract available
   
   
5. HE T, Sun H, Zong L
   Type 1 Autoimmune Pancreatitis with Associated Ulcerative Colitis in a 65-year-old Male.
   Dig Dis Sci. 2026 Mar 21. doi: 10.1007/s10620-026-09839.
   PubMed        
   
   
6. VATTIKONDA A, Odah T, Crosby S, Hashash JG, et al
   Outcomes of Risankizumab in Patients with Crohn's Disease and Prior Ustekinumab Exposure in a Multicenter Academic Institution.
   Dig Dis Sci. 2026 Mar 25. doi: 10.1007/s10620-026-09851.
   PubMed         Abstract available
   
   
7. RONEY AR, Orr D, Barghi A, Hussani S, et al
   Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the Treatment of Inflammatory Bowel Disease.
   Dig Dis Sci. 2026 Mar 24. doi: 10.1007/s10620-026-09797.
   PubMed         Abstract available
   
   

   
   Eur J Gastroenterol Hepatol

8. DEYHIM T, Saraga A, Gade A, Geeganage G, et al
   Lower drug clearance of adalimumab is associated with proactive therapeutic drug monitoring and mucosal healing in patients with inflammatory bowel disease.
   Eur J Gastroenterol Hepatol. 2026 Mar 23. doi: 10.1097/MEG.0000000000003183.
   PubMed         Abstract available
   
   
9. OIWA K, Yamamura T, Nakamura M, Maeda K, et al
   Total biopsy via endoscopic submucosal dissection is useful for the diagnosis of neoplastic lesions in patients with ulcerative colitis.
   Eur J Gastroenterol Hepatol. 2026 Feb 26. doi: 10.1097/MEG.0000000000003165.
   PubMed         Abstract available
   
   
10. ZEWDU WS, Zerihun TE, Emiru ZA, Dagnew SB, et al
    Medication adherence level and its predictors among inflammatory bowel disease sufferers in a resource-strained healthcare setting.
    Eur J Gastroenterol Hepatol. 2026 Mar 6. doi: 10.1097/MEG.0000000000003166.
    PubMed         Abstract available
    
    
11. RZETELNA H, Santo P, de Souza HSP, Nichols J, et al
    Positive conversion of latent tuberculosis screening in patients with inflammatory bowel disease on antitumor necrosis factor alpha drugs: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2026 Mar 23. doi: 10.1097/MEG.0000000000003180.
    PubMed         Abstract available
    
    

    
    Gastroenterology

12. DANNE C, de Oliveira Formiga R, Creusot L, Marquet F, et al
    Faecalibacterium prausnitzii Induces an Anti-inflammatory Response and a Metabolic Reprogramming in Human Monocytes.
    Gastroenterology. 2026;170:704-720.
    PubMed         Abstract available
    
    

    
    Inflamm Bowel Dis

13. RAMAKRISHNAN P, Campbell J, Moutsoglou D, Ghai M, et al
    Discordant Clostridioides difficile testing as a predictor of inflammatory bowel disease therapy escalation.
    Inflamm Bowel Dis. 2026 Mar 25:izag038. doi: 10.1093.
    PubMed         Abstract available
    
    
14. FAROOQ A, Naveed M, Chowdhury R, Seminerio J, et al
    Enhancing Inflammatory Bowel Disease (IBD) competency in gastroenterology fellowship through traditional, digital, and experiential learning pathways.
    Inflamm Bowel Dis. 2026 Mar 22:izag043. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Clin Gastroenterol

15. CHOU C, Sanchirico M, Mukherjee RS, Hudesman D, et al
    Defining Moderate Disease Activity and Severity in Crohn's Disease and Ulcerative Colitis.
    J Clin Gastroenterol. 2026 Mar 24. doi: 10.1097/MCG.0000000000002349.
    PubMed         Abstract available
    
    
16. DOU Q, Yao Y, Liu L
    Comments on "Increased Prevalence of Pulmonary Diseases in Patients With Inflammatory Bowel Disease: A Retrospective Multicenter Study".
    J Clin Gastroenterol. 2026 Mar 23. doi: 10.1097/MCG.0000000000002363.
    PubMed        
    
    

    
    J Crohns Colitis

17. PEREZ-GALINDO P, Gisbert JP, Carrillo-Palau M, Bertoletti F, et al
    Influence of vedolizumab on extraintestinal manifestations in inflammatory bowel disease: a nationwide multicenter study of the GETECCU ENEIDA Registry.
    J Crohns Colitis. 2026;20:jjag024.
    PubMed         Abstract available
    
    
18. MENINGHER T, Finkel O, Nayshool O, Fudim E, et al
    Transcriptomic profiling of fecal aspirates as a tool for prediction of endoscopic inflammation in small bowel Crohn's disease.
    J Crohns Colitis. 2026;20:jjag026.
    PubMed         Abstract available
    
    
19. WENDT ER, Liang Y, Park G, Hindmarch DC, et al
    Filgotinib treatment modulates frequency and gene expression of circulating immune cell subsets in ulcerative colitis.
    J Crohns Colitis. 2026;20:jjag028.
    PubMed         Abstract available
    
    
20. MORAES BF, Leite GAPD, Visentini LM, Leite GAPD, et al
    Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis.
    J Crohns Colitis. 2026;20:jjag035.
    PubMed         Abstract available
    
    
21. DE CRISTOFARO E, Marafini I, Monteleone G
    Dysplasia in inflammatory bowel disease pseudopolyps.
    J Crohns Colitis. 2026;20:jjag016.
    PubMed        
    
    
22. LIM CT, Pruijt M, Lim GH, Jamaludin F, et al
    Transperineal ultrasonography in detecting penetrating perianal disease: a systematic review and meta-analysis.
    J Crohns Colitis. 2026;20:jjag032.
    PubMed         Abstract available
    
    
23. NIYIGENA E, Hoffert Y, Afif W, Pedicelli A, et al
    Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis.
    J Crohns Colitis. 2026;20:jjag029.
    PubMed         Abstract available
    
    
24. HUDSON AS, Isaac DM, Ma H, Kuc A, et al
    Early intestinal ultrasound findings predict remission and treatment response at 1 year in pediatric Crohn's disease.
    J Crohns Colitis. 2026;20:jjag036.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

25. DONG B, Hou L
    Letter to "Increasing age at diagnosis raises malignancy risk and aminosalicylate intolerance influences therapeutic strategies in ulcerative colitis".
    J Gastroenterol. 2026 Mar 27. doi: 10.1007/s00535-026-02378.
    PubMed        
    
    

    
    Scand J Gastroenterol

26. SOMMERVOLL FA, Songstad MME, von Volkmann HL, Nylund K, et al
    Comparison of endoscopy and mobile health index for ulcerative colitis.
    Scand J Gastroenterol. 2026 Mar 25:1-9. doi: 10.1080/00365521.2026.2645085.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum